EGFR and non-small cell lung carcinoma: Similarly, when the treatment studied is a targeted therapy, such as the EGFR tyrosine-kinase inhibitor erlotinib, a reduction in SUVmax measured by [18F]-FDG-PET is also clearly associated with durable therapeutic responses in NSCLC patients (29).